European Medicines Agency puts Pradaxa deaths in to perspective
This article was originally published in Scrip
The European Medicines Agency is updating the safety information for Boehringer Ingelheim's warfarin-replacement anticoagulant Pradaxa (dabigatran) following reports that 256 patients taking the drug had died due to serious bleeding. However, the agency is not unduly concerned. It points out that the deaths have occurred following increased uptake thanks to the approval of the new stroke prevention indication.
You may also be interested in...
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.